ScinoPharm and CVie Therapeutics Limited to Jointly Develop New Heart Failure Drug
TAINAN, , Aug. 5, 2016 /PRNewswire/ -- ScinoPharm Taiwan, Ltd (TWSE: 1789) and CVie Therapeutics Limited (CVie) jointly announced the initiation of a discovery and development collaboration to identify the new generation compound to Istaroxime, CVie's acute heart failure treatment currently in la...
ScinoPharm Reports Financial Performance for 2015
TAINAN, , Feb. 14, 2016 /PRNewswire/ -- ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2015. The consolidated revenue wasNT$3.955 billion (US$124.6 million), after-tax net ...
ScinoPharm Changshu Site Completed US FDA Inspection
TAINAN, , Nov. 9, 2015 /PRNewswire/ -- ScinoPharm (TWSE:1789) today announced that its subsidiary, ScinoPharm Changshu, located in the Changshu Economic Development Zone inJiangsu Province, China, has successfully completed a cGMP inspection by the US FDA with no resulting 483 concerns or comment...
ScinoPharm to Engage in Strategic Collaboration with Raffles
CHANGSHU, China, June 22, 2015 /PRNewswire/ -- ScinoPharm Taiwan, Ltd. (TWSE: 1789) and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API). By combining the R&D expertise of Raffle...
ScinoPharm Taiwan and Coland Holdings Establish Strategic Alliance for Oncological Injectable Products for China
TAINAN, May 10, 2013 /PRNewswire/ -- ScinoPharm Taiwan Ltd.( http://www.scinopharm.com ) (TSE: 1789.TW) and Coland Holdings Ltd.( http://www.colandpharma.com ) (TSE: 4144.TW) announced today that they have formed a strategic alliance to develop a series of generic oncological drugs for Mainland Chin...
ScinoPharm to Provide Contract Manufacturing Services for VIVUS' Newly-Approved Anti-Obesity Drug, Qsymia(TM)
TAINAN, July 19, 2012 /PRNewswire-Asia/ -- ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for VIVUS' Qsymia(TM), a new drug for the treatment of obesity approved by the United States...
